Melatonin & Zolpidem Interaction

Melatonin (an endogenous hormone supplement) and zolpidem (a non-benzodiazepine sedative-hypnotic) are both used for insomnia. Concurrent use can produce additive central nervous system (CNS) depression, increasing risks of excessive sedation, psychomotor impairment, and next-day cognitive effects. While melatonin is available without a prescription, the combination with zolpidem should be discussed with a healthcare provider.

Zolpidem acts as a positive allosteric modulator of GABA-A receptors (via the benzodiazepine binding site), producing sedation and anxiolysis. Melatonin acts on MT1 and MT2 receptors in the suprachiasmatic nucleus to regulate circadian rhythm and sleep onset. The mechanisms are distinct pharmacologically, but both produce CNS depressant effects. Additive sedation is the primary concern rather than a pharmacokinetic drug-drug interaction.

Case reports and pharmacodynamic studies suggest that combining melatonin with zolpidem enhances sedation beyond either agent alone. The FDA label for zolpidem already carries warnings about CNS depression and next-morning impairment (especially with the extended-release formulation). Adding melatonin may further impair driving ability, reaction time, and cognitive function the following morning.

If melatonin is used alongside zolpidem, start melatonin at the lowest effective dose (0.5–1 mg) given 30–60 minutes before bedtime. Take zolpidem immediately before bed per label. Avoid alcohol. Counsel patients not to drive or operate heavy machinery the next morning until they know how the combination affects them. Consider whether both agents are necessary or whether one can replace the other.

Daytime sedation and cognitive function assessment. Driving ability and psychomotor testing if indicated. Sleep diary or validated scale (Insomnia Severity Index) to assess efficacy. Monitor for rebound insomnia if zolpidem is discontinued.

Cognitive behavioral therapy for insomnia (CBT-I) is the first-line treatment for chronic insomnia. If pharmacotherapy is needed, using either melatonin or zolpidem alone (not both) is preferable. Low-dose doxepin, ramelteon (MT1/MT2 agonist), or suvorexant are alternatives depending on the insomnia subtype.